Experts discuss the frequency of cystectomy use in patients with non–muscle-invasive bladder cancer (NMIBC) and how often patients are requesting bladder-sparing treatments.

Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic ...

"[Urologists] really need to understand how big the prostate is and how big of a surgery that they're looking at," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, shares her perspective ...

Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy ...

In this video, Gopa Iyer, MD, shares the background and preliminary findings from the phase 1/2 SURF301 (NCT05544552) trial of TYRA-300 in advanced/metastatic urothelial carcinoma.Iyer is a ...

On January 28, 2025, and February 25, 2025, Urology Times conducted case-based roundtable discussions on the topic of upper tract urothelial cancer (UTUC). The programs were moderated by Katie S.

ABO-101 received orphan drug and rare pediatric disease designations for PH1, targeting the HAO1 gene to reduce oxalate production. Ibex Prostate Detect, an AI-powered diagnostic tool, achieved 510(k) ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.” In this video, Francesca ...

"I would say, talk to each other. Talk to other men about it. You are not the only one leaking," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, gives advice to men with ...

Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).

“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD. In ...